Enanta Pharmaceuticals (NASDAQ:ENTA) Receives Market Outperform Rating from JMP Securities

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “market outperform” rating reaffirmed by equities researchers at JMP Securities in a research note issued on Wednesday, Benzinga reports. They currently have a $22.00 price target on the biotechnology company’s stock. JMP Securities’ target price suggests a potential upside of 106.19% from the stock’s current price.

ENTA has been the subject of a number of other research reports. JPMorgan Chase & Co. decreased their target price on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a research report on Tuesday, August 6th. Evercore ISI raised shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.00.

Enanta Pharmaceuticals Stock Down 3.0 %

Shares of ENTA stock traded down $0.33 on Wednesday, reaching $10.67. The company had a trading volume of 92,190 shares, compared to its average volume of 207,592. The stock has a market capitalization of $225.98 million, a PE ratio of -1.71 and a beta of 0.58. Enanta Pharmaceuticals has a one year low of $8.08 and a one year high of $17.80. The business’s 50-day moving average is $12.14 and its 200 day moving average is $13.28.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The company had revenue of $17.97 million during the quarter, compared to the consensus estimate of $17.44 million. During the same quarter in the prior year, the firm posted ($1.27) earnings per share. The firm’s revenue was down 4.9% compared to the same quarter last year. On average, sell-side analysts forecast that Enanta Pharmaceuticals will post -5.3 earnings per share for the current fiscal year.

Insider Transactions at Enanta Pharmaceuticals

In other news, insider Scott T. Rottinghaus sold 4,299 shares of the firm’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $15.07, for a total transaction of $64,785.93. Following the completion of the sale, the insider now owns 23,988 shares of the company’s stock, valued at $361,499.16. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, insider Scott T. Rottinghaus sold 5,375 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $17.08, for a total value of $91,805.00. Following the transaction, the insider now directly owns 21,717 shares in the company, valued at $370,926.36. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Scott T. Rottinghaus sold 4,299 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $15.07, for a total value of $64,785.93. Following the completion of the transaction, the insider now owns 23,988 shares in the company, valued at approximately $361,499.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 13.64% of the company’s stock.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Farallon Capital Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 3.5% in the 1st quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock worth $36,579,000 after purchasing an additional 70,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Enanta Pharmaceuticals by 7.5% in the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after purchasing an additional 134,292 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 1.3% in the 1st quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock worth $14,906,000 after purchasing an additional 10,952 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Enanta Pharmaceuticals by 13.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock valued at $958,000 after acquiring an additional 8,645 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its stake in Enanta Pharmaceuticals by 65.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after acquiring an additional 18,003 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.